CinCor Pharma, Inc.

Share · US17240Y1091 · CINC (XNAS)

Overview

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

n/a

Share Float & Liquidity

Free Float 40,92 %

Shares Float 17,91 M

Shares Outstanding 43,76 M

Company Profile for CinCor Pharma, Inc. Share

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

AI Analysis of CinCor Pharma, Inc.

Click any analysis below to get instant AI insights from finAgent

Latest AI Analyses of CinCor Pharma, Inc.

No AI threads available for this company yet.

Company Data

Name CinCor Pharma, Inc.

Company CinCor Pharma, Inc.

Symbol CINC

Website https://www.cincor.com

Primary Exchange

NASDAQ

ISIN US17240Y1091

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Marc M. P. de Garidel

Market Capitalization 1 Mrd.

Country United States of America

Currency USD

Employees 0,0 T

Address 200 Clarendon Street, 02116 Boston

IPO Date 2022-01-07

Ticker Symbols

Name	Symbol
NASDAQ	CINC

More Shares

Investors who hold CinCor Pharma, Inc. also have the following shares in their portfolio:

ADALTA LTD O.N. Share

Norddeutsche Landesbank -GZ- FLR-Inh.-Schv.Ser.1843v.15(26) Unbekannt

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog